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Abstract
Liver cancer is the 6th most common cancer and 2nd leading cause of cancer-related mortality. In order to improve
patient survival early tumor detection is required and this necessitates accurate screening of at risk individuals. In
this article we concisely review the methodologies employed for Hepatocellular Carcinoma (HCC) surveillance and
how their use has evolved over the last three decades. We focus attention to serum biomarkers, particularly alpha-
fetoprotein. We propose that by using an increasingly sophisticated approach to assess dynamic rates of change in
biomarkers tailored to individual patients that screening accuracy may be improved. Additional improvements may
also be possible by the incorporation of patient clinical data into such personalised screening assessments. These
possibilities may hold the promise of improving cancer detection and early curative therapy for the increasing
worldwide population at risk of HCC development.
Keywords: Hepatocellular carcinoma; Cancer screening;
Alphafetoprotein
Short Communication
Liver cancer poses an enormous and increasing burden upon
human health worldwide. Hepatocellular carcinoma (HCC) is the 6th
most common cancer and 2nd leading cause of cancer-related mortality
[1]. Crucially, cancer incidence and mortality continue to rise and
increasingly affect a younger population [2].
Primary liver cancer occurs in two main forms. The first,
Hepatocellular Carcinoma (HCC), accounts for 70-90% of all primary
liver cancer worldwide and represents a tumour formed from
hepatocytes within the liver. The other form is Intra-hepatic
Cholangiocarcinoma (ICC); a cancer of the bile ducts, which
represents 10-25% of primary liver cancers in most countries
worldwide [3,4]. The exception to this however is Thailand, where
cholangiocarcinoma is the predominant type due to the high incidence
of liver fluke infection, which is a major risk factor for ICC
development. This article will focus upon HCC, since it is the more
treatable form, and has a strong association with an identifiable
population at high risk. HCC therefore represents an excellent target
for cancer screening.
The strongest risk factor for HCC development is cirrhosis of any
cause and the majority of HCCs develop in patients with cirrhosis [5].
As symptoms from HCC develop typically once the disease has
advanced beyond the stage of effective or curative therapy, screening of
asymptomatic at risk patients has the possibility of detecting treatable
tumours and improving patient outcomes. This was demonstrated in
the only randomised controlled trial of screening for HCC, involving
over 18,000 Chinese patients with hepatitis B. Using six-monthly
bimodal screening comprising liver ultrasound imaging and the serum
biomarker AFP (alpha-fetoprotein), Zhang et al. demonstrated a
reduction in HCC mortality of 37% [6].
Since this study, and despite intensive research and debate, little
consistency in screening practices has been achieved [7]. The cost
effectiveness of HCC screening is disputed, and the efficacy of
screening tests remains poor. Recent studies have supported the role
for HCC surveillance and support its cost effectiveness [8,9].
Nonetheless the imperfections of HCC screening, combined with low
rates of enrolment of at risk patients into HCC screening, mean that
many patients develop HCC having missed the window in which their
tumour may have been effectively treated. Treatment options may be
curative either through surgical removal of the tumour (by resection or
orthotopic transplantation) or loco-regional therapy, however many
loco-regional options or pharmacological therapies are aimed at
delaying rather than curing the disease [10].
For the purpose of this discussion we will focus on how HCC
surveillance should be performed rather than in which target
population: principally patients with cirrhosis, or at high risk due to
family history, significant fibrosis associated Hepatitis C virus infection
or selected patients with Hepatitis B virus - for detailed guidance in
this we refer the reader to guidelines [11,12]. Diagnosis of HCC may
be made without tissue biopsy as cross-sectional imaging using
contrast enhanced CT or MRI has been shown to be accurate in HCC
discrimination. Nonetheless, neither imaging modality lends itself as a
screening test due to a combination of factors including cost, radiation
exposure, claustrophobia and the detection of indeterminate lesions.
Hence, other tests are typically used for initial screening to identify
patients with probable HCC. Cross sectional imaging is then used to
confirm or refute the diagnosis. Liver ultrasound is the imaging
modality of choice in screening but is often supplemented by the use of
serum biomarkers with the aim of improving early HCC detection.
Initial population screening for HCC was implemented in Japan in
1980s [13], and it is informative to track the consensus opinion offered
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by a variety of guidelines on the recommendations for screening tests
for HCC (Figure 1). In the context of such seemingly minor
adjustments to screening policies over recent decades, liver cancer
incidence has risen dramatically whilst HCC survival has remained
dismal. Current international guidelines differ in their
recommendations. The major European and US bodies recommend
that liver ultrasound alone be used for HCC surveillance [11,12].
Other international guidelines recommend the addition of at least one
serum biomarker, always including AFP (Figure 1).
Figure 1: Timeline of HCC surveillance guidelines. Guidance from:
BSG: British Society of Gastroenterology [7], AASLD: American
Association for the Study of Liver Disease [14], APASL: Asian
Pacific Association for the Study of the Liver [15], Canadian
Multidisciplinary Guideline [16], EASL: European Association for
the Study of the Liver, EORTC: European Organisation for Research
and Treatment of Cancer [12], JSH: Japanese Society of Hepatology
[17], NICE: National Institute for Health and Care Excellence, UK
[18], NCCN: National Comprehensive Cancer Network, Guidelines
Hepatobiliary Cancers [19].
Due to the relative conservation of the molecular phenotype of
HCC, it is plausible that a single or small panel of serum biomarkers
may detect the overwhelming majority of cancers [20]. Serum
biomarkers have a number of clear advantages as a screening tool; they
are minimally invasive, can be standardised and are relatively
inexpensive. A major ongoing challenge in the field of HCC
surveillance is to identify suitable serum markers and validate their
appropriate use.
Undoubtedly the best known and most widely used serum
biomarker for HCC is Alpha-fetoprotein (AFP). AFP is produced by
the embryonic yolk sac and subsequently the foetal liver, with maternal
serum levels falling rapidly after birth. Elevated maternal serum AFP
levels are used as part of screening for foetal abnormalities including
neural tube defects. AFP may be pathologically elevated by the
presence of germ cell tumours or HCC [21]. Serum AFP levels may
also be raised in chronic liver disease with high levels of hepatocyte
regeneration but remain low in the majority of patients with cirrhosis
in the absence of HCC. The use of AFP as a tumour marker for HCC
was first described in the 1960s [22]. Limitations to efficacy of AFP,
particularly with a static cut-off are numerous (Table 1) and summate
to a poor sensitivity and specificity when assessed in many clinical
trials. For this reason AFP has fallen out of favour as a screening test
(Figure 1). Nonetheless, some studies have suggested that AFP may
inform clinical decision making and lead to curative therapy of HCC
[23,24].
· Substantial proportion of HCCs do not secrete AFP, irrespective of size [25]
· AFP frequently within normal range in small (<3 cm) HCCs [26]
· Elevated AFP can occur with chronic liver disease in absence of HCC,
particularly Hepatitis C infection [27,28]
· Variable sensitivity and specificity depending on the cut-off value used [29]
· Very high AFP is a marker of poor prognosis; identifying patients with
advanced HCC [30]
End result: Poor sensitivity and specificity when tested clinically
Table 1: Limitations to efficacy of AFP
With the movement away from the use of AFP earlier this decade
and the absence of alternative serum biomarkers, the frailty of using
liver ultrasound alone as a screening test has become an increasing
concern. In many studies, the sensitivity and specificity of liver
ultrasound have been relatively poor, ranging from 60-90% and
90-95% respectively [31-33]. When used in a real world setting, the
accuracy has been even worse [34]. Therefore, with this unmet need,
there is an increasing drive to develop improved serum biomarkers for
use in the growing worldwide population of patients at high risk of
HCC development.
There is a possibility, however, that a more sophisticated
interpretation of existing biomarkers and the combination of single or
multiple biomarker levels with demographic information may
significantly improve their accuracy. This is now practically feasible as
large datasets exist which can be mined for patterns identifying
underlying HCC. For example, numerous studies have now shown that
absolute changes in AFP values from a nadir can improve accuracy
[35]. Others, including ourselves, have now shown that measuring
dynamic rates of change over time for individuals can also be used
effectively [23,36]. A further strategy has been to combine multiple
serum markers. Additional serum markers studied in this way include
the AFP-LP3 isoform, Des-gamma-carboxyprothrombin (DCP) and
Golgi protein 73 (GP73) amongst others [37]. Meta-analysis of studies
in 2013 showed that certain combinations of markers provided greater
diagnostic accuracy than each alone [38]. Never the less, variations in
biochemical assays and differing cut-offs values applied in different
retrospective studies have limited the clinical applicability of using
multiple biomarkers in most cases. However one example of a
combination of serum biomarkers used synchronously which has
moved towards validated clinical practice is by the group of Philip
Johnson [39]. They have utilised a panel of three biomarkers (AFP, its
AFP-LP3 isoform, and DCP). Importantly Johnson et al. used this
marker panel and combined it with other variables (patient age and
gender) to create the GALAD score and have now validated this in
patient cohorts from Germany, Japan and Hong Kong [40]. The
GALAD score has consistently discriminated patients with HCC from
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HCC-free patients in real world screening cohorts, with Area under
Receiver Operator Curve values of >0.90, and it is now freely available
to use via the Mayo Clinic portal. Additional optimisation is still
required, particularly for patients with small uni-focal HCCs for whom
medical therapy is most likely to be successful. It is the identification of
this population which is crucial as recent studies have clearly shown
that early detection is associated with broader treatment options and
improved survival [8]. It is possible that the further combination of
monitoring dynamic changes in these three serum biomarkers and
additional clinical information, including disease aetiology, may allow
further improvement in the accuracy of serum biomarker detection of
HCC.
An ongoing requirement is large well characterised prospectively
followed cohorts. Such data are vital to explore and validate ongoing
iterative improvements in HCC surveillance programmes. We predict
that this will lead to the eventual inclusion of multiple variables,
analysed in a dynamic fashion [23], to improve the detection of pre-
symptomatic HCC. It is likely in the short term that serum biomarkers
will continue to be used as an addition to ultrasound based screening
to identify very high risk patients in whom ultrasound may be unable
to detect an early HCC. However in the future serum biomarkers may
be used to stratify risk and possibly even negate the need for imaging
based surveillance, at least transiently, in highly selected patients. If
such strategies prove to be successful then we might see the broad
reintroduction of serum biomarkers into increasingly complex clinical
guidelines for HCC surveillance.
In conclusion, HCC presents an unmet need in worldwide disease.
In order to meet this, screening of asymptomatic patients is required.
However, this screening needs to be accurate and cost effective. Despite
having fallen out of favour, serum biomarkers may still hold the key to
improving HCC screening. Using these simple tests and basic clinical
information in an analytically more sophisticated manner, we may
make a genuine impact on the increasing mortality rates of HCC
worldwide.
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